Public Relations Committee
The Public Relations Committee is responsible for promoting CAHON events before, during and after the events. The committee is responsible for encouraging attendance through the CAHON and their individual networks, taking and sharing photos during the events, and writing meeting summaries after the events.
Ligeng Tian, MD, PhD (Chair)
Dr. Ligeng Tian received her medical degree from Beijing Medical University, China and her Doctor of Philosophy in Molecular Biology & Genetics from Weill Graduate School of Cornell University, New York. Dr. Tian completed her Internal Medicine Residency at Long Island Jewish Medical Center of Albert Einstein College of Medicine, New York, and her Medical Oncology/Hematology Fellowship at Yale Medical School, Connecticut. She is currently a practicing hematologist/oncologist at Virginia Oncology Associates.
Faye Yin, MD (Co-Chair)
Dr. Faye Yin received her medical degree from Southern Medical University (formerly First Military Medical University). She was a hematologist at Nanfang Hospital in Guangzhou prior to coming to the U.S.A. She completed internal medicine residency training at Good Samaritan Hospital, affiliated to Johns Hopkins Medical School, and hematology/oncology fellowship at National institutes of Health and National Cancer Institute. She has practiced for more than 20 years and treated patients with a diverse range of cancers and blood disorders. She has a special interest in breast and gynecologic cancer. She has published more than 20 scientific papers in journals and two chapters in textbooks. She is an oncologist and hematologist working at the Steeplechase Cancer Center at RWJ University Hospital Somerset, New Jersey.
Hui Chen, MD, PhD
Dr. Hui Chen is an Associate Professor of Medicine at Duke University. She previously worked at Memorial Sloan Kettering Cancer Center and has research interests in Molecular Biology and Precision Oncology, her work has been published extensively in peer-reviewed scientific journals. She has been a member of CAHON since 2015 and has been actively involved in CAHON community events. She is board-certified in Hematology, Oncology, and Internal Medicine. Dr. Chen is a member of professional organizations, such as the American College of Physicians, the American Society of Clinical Oncology, and the American Society of Hematology.
Peter Q. Jiang, MD, PhD
Dr. Peter Q Jiang is a Medical Oncologist/Hematologist who practiced at John B Amos Cancer Center, Piedmont Columbus Regional for more than 18 years. He is board certified in Medical Oncology, Hematology, and Internal Medicine. As a community oncologist, Dr. Jiang has collaborated with Radiation Oncologist, Surgical Oncologist, and Interventional Radiologist to utilize the state of arts technology and provide the highest quality care to surround community in Southwest Georgia and Southeast Alabama area.
Yumeng Zhang, MD
Dr. Yumeng Zhang became an assistant member of the Malignant Hematology Department at the renowned H. Lee Moffitt Cancer Center and Research Institute in 2023. Prior to this, she had completed her hematology and medical oncology fellowship training at the same institution, where she excelled as a chief fellow. An unwavering passion for cancer immunology and the research of rare cancers drives Dr. Zhang's journey into oncology.
Her innovative work in clinical trial design and translational oncology has earned her accolades such as the ASCO Young Investigator Award, the Robert A. Winn Diversity in Clinical Trials Award, and grants including the NIH K05 and the Microbiome Pilot Grant. She also participated in prestigious workshops like the ASCO/AACR Vail Workshop and the SCION Workshop.
Intrigued by the multifaceted nature of T-cell lymphoma, Dr. Zhang has outlined precise and ambitious objectives for her career. Her primary goal is to be recognized as a leading clinical investigator in the realm of T-cell lymphoma therapeutic development. Rather than solely relying on traditional treatment avenues, she emphasizes the integration of immune system modulation with targeted therapies. Such a pioneering approach sets the stage for groundbreaking therapeutic advancements in T-cell lymphoma.
Furthermore, Dr. Zhang is dedicated to refining the treatment and management strategies for rare cancers, such as cutaneous T-cell lymphoma. She aspires to develop or augment a research platform designed explicitly for these rare malignancies. This envisioned platform promises to be pivotal in addressing the current challenges associated with these uncommon diseases' management and therapeutic evolution. Endowed with a drive for cancer immunology and rare cancer research and equipped with the extensive clinical experience gained at the H. Lee Moffitt Cancer Center and Research Institute, Yumeng Zhang is well on the way to making significant contributions to the field of oncology.